Frontiers in Nutrition · May 14, 2026

Sodium-glucose co-transporter 2 inhibitors are negatively correlated with hypomagnesemia in elderly patients with type 2 diabetes

By Lin L, Jin Y, Jin L et al.

INTRODUCTION: The rapidly aging demographic is contributing to a significant increase in diabetes prevalence, particularly Type 2, which subsequently elevates the risk of hypo-magnesemia. Polypharmacy is recognized as a risk factor for hypomagnesemia, while the association between SGLT2 inhibitors (SGLT2i) and hypomagnesemia remains underreported. METHODS: To investigate this relationship, a retrospective cross-sectional study was conducted on patients aged 60 and older with Type 2 dia-betes, utilizing data from Wenzhou Central Hospital between January 2023 and December 2024. Multivariable logistic regression and propensity score match-ing (PSM) analyses were employed to compute adjusted odds ratios (ORs) for hypomagnesemia, accounting for potential confounders. RESULTS: The study enrolled 2,827 subjects with a mean age of 72.59 years, of which 485 (17.2%) were diag-nosed with hypomagnesemia. Both univariate [OR 0.481, 95% CI (0.334-0.692), p < 0.001] and multivariate [OR 0.392, 95% CI (0.267-0.576), p = 0.002] analyses revealed a negative correlation between SGLT2i use and hypomagnesemia. A similar trend was observed in the PSM analysis, with univariate [OR 0.353, 95% CI (0.230-0.540), p < 0.001] and multivariate [OR 0.325, 95% CI (0.208-0.506), p < 0.001] results. Furthermore, elevated levels of HbA1c and the administra-tion of metformin were associated with a higher incidence of hypomagnesemia, corroborating both pre-PSM and post-PSM analyses. DISCUSSION: Our findings suggest that among elderly patients, it may be prudent to consider serum mag-nesium levels when determining the appropriate glucose-lowering medication to initiate. SGLT2i is negatively correlated with hypomagnesemia.

doi.org/10.3389/fnut.2026.1790168Open accessPubMed 42221780Populations

AgingResearch.News